Quest PharmaTech Valuation
| QPT Stock | CAD 0.04 0.01 16.67% |
Quest PharmaTech seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Quest PharmaTech from analyzing the company fundamentals such as Number Of Shares Shorted of 333, return on equity of -0.12, and Shares Outstanding of 169.13 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Quest PharmaTech's price fluctuation is out of control at this time. Calculation of the real value of Quest PharmaTech is based on 3 months time horizon. Increasing Quest PharmaTech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Quest stock is determined by what a typical buyer is willing to pay for full or partial control of Quest PharmaTech. Since Quest PharmaTech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Quest Stock. However, Quest PharmaTech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.035 | Real 0.0305 | Hype 0.04 | Naive 0.0336 |
The intrinsic value of Quest PharmaTech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Quest PharmaTech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Quest PharmaTech helps investors to forecast how Quest stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Quest PharmaTech more accurately as focusing exclusively on Quest PharmaTech's fundamentals will not take into account other important factors: Quest PharmaTech Total Value Analysis
Quest PharmaTech is at this time estimated to have takeover price of 5.04 M with market capitalization of 4.23 M, debt of 1000 K, and cash on hands of 4.41 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Quest PharmaTech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.04 M | 4.23 M | 1000 K | 4.41 M |
Quest PharmaTech Asset Utilization
One of the ways to look at asset utilization of Quest is to check how much profit was generated for every dollar of assets it reports. Quest PharmaTech holds a negative application of assets of -0.0197 pct., losing C$1.97E-4 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Quest PharmaTech shows how discouraging it operates for each dollar spent on its assets.Quest PharmaTech Ownership Allocation
Quest PharmaTech owns a total of 169.13 Million outstanding shares. Quest PharmaTech holds 17.06 pct. of its outstanding shares held by insiders and 0.0 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Quest PharmaTech Profitability Analysis
Net Loss for the year was (3.02 M) with profit before overhead, payroll, taxes, and interest of 0.About Quest PharmaTech Valuation
Our relative valuation model uses a comparative analysis of Quest PharmaTech. We calculate exposure to Quest PharmaTech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Quest PharmaTech's related companies.Quest PharmaTech Inc., a biotechnology company, develops and commercializes antibody based immunotherapeutic products for cancer. The company also owns the Photodynamic therapy technology for oncology and dermatology applications and develops Mab AR 9.6 against truncated O-glycan on MUC16 for targeted cancer therapy applications. QUEST PHARMATECH operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange.
Additional Tools for Quest Stock Analysis
When running Quest PharmaTech's price analysis, check to measure Quest PharmaTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest PharmaTech is operating at the current time. Most of Quest PharmaTech's value examination focuses on studying past and present price action to predict the probability of Quest PharmaTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest PharmaTech's price. Additionally, you may evaluate how the addition of Quest PharmaTech to your portfolios can decrease your overall portfolio volatility.